Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Henry Dunant Hospital · Forthnet (Greece) · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials.
Methods
We randomly assigned 185 patients with chronic hepatitis B who were negative for hepatitis B e antigen (HBeAg) to receive either 10 mg of adefovir dipivoxil or placebo once daily for 48 weeks in a 2:1 ratio and a double-blind manner. The primary end point was histologic improvement.
Citation impact
999
total citations
- FWCI
- 69.64
- Percentile
- 100%
- References
- 23
Citations per year
Authors
13- SJStephanos J. HadziyannisCorresponding
Henry Dunant Hospital, Forthnet (Greece)
- NCNicolaos C. Tassopoulos
Western Attica General Hospital
- EJE. Jenny Heathcote
University of Toronto, Toronto Western Hospital
- TCTing‐Tsung Chang
National Cheng Kung University Hospital
- GKG. Kitis
G. Papanikolaou General Hospital
Topics & keywords
Topics
Keywords
- Adefovir
- Medicine
- Gastroenterology
- HBeAg
- Internal medicine
- Placebo
- Hepatitis B
- Hepatitis B virus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.